Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study

November, 04 2021

BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal (“BET”) inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time. VYNE is evaluating its lead BET inhibitor, VYN201, for several autoimmune skin diseases that are characterized by lesions, such as chronic ulcers and blisters, which are challenging to treat and can potentially lead to severe infections and surgical intervention. Frequently used treatments for neutrophilic dermatoses are…

Read More